News Articles February 2022
Written on 04 February 2022.
News Articles October 2025
News Articles October 2025
When Cushing’s becomes cancer: metastasis or induced by radiation?
An article in Cushing’s Disease News looks at a study that examines the case of two women whose benign tumors associated with Cushing’s disease turned malignant. The question is whether they metastasized or if radiation could have induced the transformation. More info: https://cushingsdiseasenews.com/news/cushings-pituitary-tumors-rarely-aggressive-cancers/
Pituitary apoplexy: symptomatic vs asymptomatic
A study in the Journal of Clinical Neuroscience looks at the clinical profile of patients with and without symptoms of pituitary apoplexy. Symptoms include “headache, vomiting and cranial nerve palsies.” People without symptoms who suffered pituitary apoplexy had lower white blood cell counts and lower blood sodium levels. Read more: https://www.sciencedirect.com/science/article/abs/pii/S0967586825005983
When a pituitary macroadenoma causes sepsis-like symptoms
A study on Cureus.com presents a case report where a woman was initially treated for sepsis but turned out to have a pituitary macroadenoma. Read more: https://assets.cureus.com/uploads/case_report/pdf/413034/20250912-112610-bm0ldk.pdf
Acute Sheehan’s Syndrome after post-partum pituitary hemorrhage
A case study presented on Cureus.com looks at the patient who gave birth, suffered a pituitary hemorrhage, and developed acute Sheehan’s Syndome and then pituitary atrophy eight months postpartum. Read more: https://assets.cureus.com/uploads/case_report/pdf/411201/20250914-401650-bm0ldk.pdf
PNA Highlights October 2025
“Take a few minutes each and every day to ensure that your mind is nourished properly and positively. After all, a healthy mind leads to a happier view of life and with a happier view of life it is much easier to counter the negative impact other issues will have on us.” – Catherine Pulsifer
PNA Spotlight: Dr. Jamie Van Gompel
This month the PNA Spotlight focuses on longtime PNA member Dr. Jamie Van Gompel, a neurosurgeon at Mayo Clinic in Rochester, Minnesota. Dr. Van Gompel earned a B.S. in molecular biology, biochemistry, medical microbiology and immunology, and then his M.D. at the University of Wisconsin. He earned a certificate in Clinical and Translational Research at Mayo Clinic, where he also did residencies as a clinician investigator and in neurologic surgery. He then completed a fellowship in skull base and complex cranial surgery at the University of South Florida. He was kind enough to answer some questions from the PNA.
Tell us about your educational journey.
At the University of Wisconsin as an undergraduate, I did a couple of majors, including molecular biology, immunology and medical microbiology and then biochemistry. When I found out at college that you could pay the same amount and take over 18 credits, I would load up, so I got all those in four years. In between my undergraduate work and medical school, I worked for the National Institutes of Health (NIH) for a period of time. I was really interested in infectious diseases, so I worked at the Rocky Mountain Lab in Montana, researching bacteria. It served as a high-level pathogen facility, much like the one at the Centers for Disease Control in Atlanta. So, it’s a cool place to work; I really enjoyed it. And then we could go fly fishing at lunchtime on the river. It was fun.
Read More Here
Cushing’s Disease and the Role of Multidisciplinary Care
For many patients facing pituitary challenges, the road to a diagnosis of Cushing’s disease can be a long and frustrating one. Symptoms tend to develop slowly, often resembling more common conditions such as weight gain, high blood pressure, diabetes, or mood changes. By the time patients learn they have a pituitary tumor, they may have already lived with years of uncertainty.
“One of the key challenges in Cushing’s disease is that it’s very hard to diagnose, and there are often long diagnostic delays,” said Dr. Aditi Kumar, endocrinologist at Mayo Clinic. “The symptoms are very slow in onset, and they may mimic common conditions like diabetes, hypertension, obesity, depression, or anxiety. And it’s a very rare condition as well.”
Cushing’s disease occurs when a small, benign tumor in the pituitary gland causes excess production of cortisol, a hormone that regulates many of the body’s functions. Because stress and certain medications can also affect cortisol levels, testing to confirm the disease is complex. It often involves blood tests, urine tests, and salivary cortisol testing. The results can be challenging to interpret, making referral to an expert endocrinologist especially important when Cushing’s is suspected.
“Our team at Mayo Clinic has extensive experience with inferior petrosal sinus sampling, a test that can help determine whether excess cortisol is coming from the pituitary gland,” said Dr. Bernard Bendok, neurosurgeon and chair of neurosurgery at Mayo Clinic in Arizona.
Treatment usually begins with surgery to remove the tumor. “After that, patients must be followed very closely because even after initial surgery, there’s a chance that the condition can recur,” Dr. Kumar said. “It also has a huge impact on the mental and emotional health of patients, so they need a lot of support during the whole process of diagnosis, treatment, and recovery.”
At Mayo Clinic, that support comes from surrounding the patient with a diverse team of experts. “Our strength is that we have a multidisciplinary team of specialists to take care of these patients,” Dr. Kumar said. Endocrinologists work alongside neurosurgeons, neuroradiologists, neuro-ophthalmologists, ENT specialists, and radiation oncologists. Mayo also uses advanced tools such as seven-Tesla MRI, which can detect very small tumors that may not be visible on standard scans.
Advances in surgical techniques have further improved outcomes. “Advancements in endoscopic surgery have significantly enhanced the visualization of the pituitary gland, making surgeries for Cushing’s disease more precise,” said “Additionally, the integration of virtual and augmented reality has revolutionized our ability to incorporate preoperative imaging into the surgical plan in real time. Access to world-class neuropathology is crucial for intraoperative decision-making. The use of intraoperative ultrasound is an exciting new frontier, aiding in the detection of very small lesions,” Dr. Bendok added.
Researchers at Mayo Clinic are also exploring robotic approaches to make surgery even more precise in and around the pituitary gland, further advancing patient care.
Mayo’s high-tech, team-focused approach also helps patients avoid repeated visits and delays. “We try to bundle up appointments so that patients are able to make the most of their visit and that diagnosis and treatment can proceed very quickly,” Dr. Kumar said.
Even after surgery, most patients continue to need close attention. Larger or more invasive tumors may not be able to be completely removed, and Cushing’s disease can recur. This is why ongoing follow-ups are essential. With Mayo’s multidisciplinary team and long-term support, patients can face Cushing’s disease with more hope and clarity, knowing they are not alone in their journey.
For more information or to request an appointment, please visit Pituitary Tumor Care – Mayo Clinic
PNA Medical Corner: Sinonasal Quality of Life After Pituitary Surgery
This month the PNA Medical Corner showcases a study coauthored by Dr. Juan Fernandez-Miranda at Stanford University, a member of the PNA. The study finds that patients with functional tumors have a longer period of healing in the sinus cavity, compared to patients with non-functional tumors.

Dr. Juan Fernandez-Miranda
. 2025 Sep 17.
doi: 10.1002/lary.70116. Online ahead of print.
Functionality of Pituitary Tumors Impacts Sinonasal Quality of Life Before and After Endoscopic Surgery
Yossawee Wongworawut 1, Peter H Hwang 2, Jayakar V Nayak 2, Robert Dodd 3, Juan C Fernandez-Miranda 3, Zara M Patel 2
Affiliations Expand
• PMID: 40960129 DOI: 10.1002/lary.70116
Abstract
Objectives: Local effects of pituitary hormones in the sinonasal region are not well characterized. We sought to examine sinonasal quality of life outcomes in functional and non-functional pituitary tumors after endoscopic skull base surgery.
Study design: Retrospective Medical Record Review.
Methods: Three hundred four patients who received endoscopic resection of a pituitary tumor at a tertiary skull base center reviewed. This population was divided into non-functional and functional groups. Surgical outcomes and pre and postoperative quality of life scores were examined.
Results: Preoperative total SNOT 22 scores were not different overall between the two groups, but the rhinologic and extra-nasal rhinologic subdomain scores in the functional group were higher than in the non-functional group (3.57 ± 3.95 vs. 2.58 ± 3.64, and 1.48 ± 2.2 vs. 0.92 ± 1.75 respectively) (p = 0.04 and 0.02). Change from baseline in overall postoperative SNOT 22 score was significantly greater in the functional group at 6 weeks post-operation (6.75 ± 17.51 vs. 1.4 ± 16.83 respectively) (p = 0.03). Time to normalization on nasal endoscopy was longer in the functional group compared to the non-functional group (p = 0.02).
Conclusion: Corticotrophic and somatotrophic tumors affect quality of life both pre- and post-operation. Patients with functional tumors took longer to reach full healing and normalization of the sinus cavity. These findings can be used to counsel patients about different expectations during the immediate postoperative healing period, but also to reassure them that regardless of tumor functionality, they will be able to reach a good quality of life after endoscopic skull base surgery.
Keywords: pituitary adenoma; pituitary tumor; sinonasal outcome test; skull base; skull base neoplasm.
© 2025 The American Laryngological, Rhinological and Otological Society, Inc.
Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support
Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.
Sign up to get dedicated support:
Patients: Sign up for support | Recorlev® (levoketoconazole)
HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)
Have more questions? Call for more support at 1-844-444-RCLV (7258)
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.
October 2025 Research Articles
Pituitary tumors
Galliano SA, Stumpf MAM, Queiroz NL, Ferreira EHR, Craveiro FL, Gruetzmacher C, Silva GOD, Cescato VAS, Vellutini EAS, Cunha-Neto MBC, Batista RL, Glezer A.Einstein (Sao Paulo). 2025 Sep 15;23:eAO1694. doi: 10.31744/einstein_journal/2025AO1694. eCollection 2025.
The evolution and application of multi-omic analysis for pituitary neuroendocrine tumors.
Pugazenthi S, Pari SS, Zhang Z, Silverstein J, Kim AH, Patel B.Front Med (Lausanne). 2025 Sep 1;12:1629621. doi: 10.3389/fmed.2025.1629621. eCollection 2025.
Limitations of MRI in differentiating solid and cystic components of craniopharyngiomas.
Karaalioğlu B, Öksüz NÇ, İpek V, Çakır A, Kahraman O, Özbek MA.Childs Nerv Syst. 2025 Sep 16;41(1):281. doi: 10.1007/s00381-025-06941-y.
Krishna MSV, Babu DVSP, Singh M, Madhavan S.Cureus. 2025 Aug 13;17(8):e89995. doi: 10.7759/cureus.89995. eCollection 2025 Aug.
Cushing’s Disease
Changing face of Cushing’s disease over three decades in pituitary center.
Muradov I, Sahin S, Uysal S, Sulu C, Gunebakan P, Tunc A, Kocaman BB, Soltanova L, Gazioglu N, Tanriover N, Kadioglu P.J Endocrinol Invest. 2025 Sep 16. doi: 10.1007/s40618-025-02702-5. Online ahead of print.
Editor’s note: Dr. Gazioglu is a member of the PNA.
Update on Medical Treatment of Cushing’s Syndrome.
Dillon BR, Agrawal N, Schwarz Y, Dancel-Manning K, Tabarin A, Lacroix A, Hofland LJ, Feelders RA.Drugs. 2025 Sep 15. doi: 10.1007/s40265-025-02223-8. Online ahead of print.
Acromegaly
Tagilapalli SK, Wang Z, Lu YL, Zhang G, Su W, Wu Z, Wang J, Rao Q, Wang H, He D, Mou Y, Yao S, Tie Y, Chen W.CNS Neurosci Ther. 2025 Sep;31(9):e70607. doi: 10.1111/cns.70607.
Imaging
Tian Y.JMIR AI. 2025 Sep 15;4:e76344. doi: 10.2196/76344.
Hormonal health
Cheng X, Xiao Y, Deng Y, Chen Q, Wen X, Zhou E, Zhou H.PLoS One. 2025 Sep 18;20(9):e0332871. doi: 10.1371/journal.pone.0332871. eCollection 2025.
Geremia C, Geremia F.J Pediatr Endocrinol Metab. 2025 Jul 21;38(9):904-914. doi: 10.1515/jpem-2025-0082. Print 2025 Sep 25.
PNA Spotlight: Dr. Jamie Van Gompel
PNA Spotlight: Dr. Jamie Van Gompel
This month the PNA Spotlight focuses on longtime PNA member Dr. Jamie Van Gompel, a neurosurgeon at Mayo Clinic in Rochester, Minnesota. Dr. Van Gompel earned a B.S. in molecular biology, biochemistry, medical microbiology and immunology, and then his M.D. at the University of Wisconsin. He earned a certificate in Clinical and Translational Research at Mayo Clinic, where he also did residencies as a clinician investigator and in neurologic surgery. He then completed a fellowship in skull base and complex cranial surgery at the University of South Florida. He was kind enough to answer some questions from the PNA.
Tell us about your educational journey.
At the University of Wisconsin as an undergraduate, I did a couple of majors, including molecular biology, immunology and medical microbiology and then biochemistry. When I found out at college that you could pay the same amount and take over 18 credits, I would load up, so I got all those in four years. In between my undergraduate work and medical school, I worked for the National Institutes of Health (NIH) for a period of time. I was really interested in infectious diseases, so I worked at the Rocky Mountain Lab in Montana, researching bacteria. It served as a high-level pathogen facility, much like the one at the Centers for Disease Control in Atlanta. So, it’s a cool place to work; I really enjoyed it. And then we could go fly fishing at lunchtime on the river. It was fun.
Later, I went to University of Wisconsin at Madison for medical school. I started out wanting to be a general surgeon, and I was very interested in neuroendocrine diseases. I was working on carcinoid tumors and medullary thyroid tumors, because I thought that it was really cool to tackle a challenging surgical disease, with secreting tumors; something that has medical impact. I even took a year doing a Howard Hughes Fellowship in research with my mentor Dr. Herb Chen, which was very formative after my clinical year in medical school (year 3). It was during this formative time that I decided to transition my interest from general surgery to neurologic surgery.
I finished medical school and came up to Mayo Clinic in Rochester, Minnesota for my residency. I did a seven-year residency here, and as part of my education within that, I did the Translational Studies Program, which teaches people how to do research and clinical trials. I was asked to stay on staff here as a skull-base and epilepsy neurosurgeon. I did a complex cranial fellowship with Dr. Harry van Loveren in South Florida.
At the end of that fellowship, I was playing softball with USF in New York City, and I broke my hand. This led to more education, since I broke my hand before I started at Mayo Clinic. My boss, mentor and chair at Mayo Clinic at the time, Dr. Fred Meyer, said, “Hey, since you broke your hand, you can’t operate. I’ll send you around. What do you want to do?” And I said, “Well, I’d like to go see all these big-time people in pituitary surgery from across the world.” So, I traveled to see Paulo Cappabianca and Luigi Cavallo out in Napoli, Italy. I was also able to visit with people like the Pittsburgh group (Paul and Juan), Dan Prevedello at OHSU and Ted Schwartz in New York. I was able to sample how everyone was doing pituitary surgery at the time. My hand healed and I returned to Mayo Clinic; that was 14 years ago. It kind of backs the Taoist fable of the Chinese man who lost his horse, in which when something bad happens but it turns out alright. When I broke my hand, it seemed bad, but in this circumstance, it turned out to be a blessing. So, you just never know how things will work out.
Who were your primary mentors?
I think all of us have a ton of mentors. I’ve always admired Dr. Ed Laws. I’ve always looked up to his work, because he started at Mayo Clinic and was very interested in pituitary disease, as I am. Also, Drs. Fred Meyer and John Atkinson, two pituitary surgeons at Mayo Clinic, are big mentors of mine here who taught me a lot. And my other mentors are Dr. Van Loveren, Dr. Agazzi, and Dr. Sammy Youssef, who were in South Florida. I want to acknowledge Dr. Michael Link, who’s here at Mayo Clinic as well.
Why choose pituitary surgery?
I love doing pituitary surgery. I tell a lot of my patients that if I if I got independently wealthy tomorrow, if I hit the Powerball, I would still be a neurosurgeon and perform pituitary tumor surgeries. I might even pay people to be able to do the surgery! I really enjoy the complexity of it, not only the surgical complexity, but also the management of the patients, pre- and post-operatively. I like the fact that we can help them improve for the rest of their lives.
What do you see as the future of your field?
We are trying to understand what gives us good outcomes, and how we can improve that. I think there’s a lot of progress to be made with machine learning and Artificial Intelligence (AI), which we can use to help patients diagnosed with pituitary tumors. Right now, we do a lot of data granularity, through Mayo Clinic and a database that we developed called MAPER, the Mayo Adenoma Pituitary Enterprise Registry. We also work with the RAPID Consortium. These are trying to collect large amounts of data to determine what really, truly impacts pituitary outcomes for patients. Also, I’m fortunate enough at Mayo Clinic to see also the very uncommon cases, and we still study them quite a bit to see how we can do better with those as well. The focus of my research is just better patient outcomes, and that includes not only having the tumor gone, but better endocrine outcomes and better life outcomes for patients.
Is there a role for robotics in pituitary surgery?
We use robots, but not for pituitary surgery. Nowadays, we’re using it for epilepsy and some other things. I don’t think that pituitary surgery is going to be supplanted by some super robot in the future, very soon. But I do think that AI is integrating data and seeing things at a pace that people just can’t. I think that AI is going to be an important thing for all medical fields. And pituitary medicine will benefit from that. I think good pituitary surgeons can look at things and do a lot of risk assessments. Most of these things will be just aiding pituitary surgeons in their risk assessment and can put all the data at their fingertips. It will help enhance our memory to understand how good our outcomes can be, or maybe to be more realistic in some circumstances.
We have seen great progress in pituitary medicine. Maybe 10 years ago we would have removed a little bit of the tumor and left some behind. Whereas nowadays we can, at the same risk, remove all the tumor and avoid other therapies that they just couldn’t do back then. We can credit technological advances and a better understanding of the anatomy and of medical treatments.
Why are you involved with the PNA?
I love the PNA’s mission. Doctors sometimes talk at such a high-level, and we need to really connect with patients. The PNA helps us prioritize what’s important to the patients and hear what they’re saying and what they need. The information is modeled in a different way that isn’t so technical. I think it is really important to have patient-facing enterprises like PNA. I’ve been a PNA member now for over 13 years, and I think that I’ve learned as much from the PNA as they’ve learned from me.
PNA Highlights October 2024
“Your body holds deep wisdom. Trust in it. Learn from it. Nourish it. Watch your life transform and be healthy.”
– Bella Bleue
PNA Spotlight: Dr. Yuval Eisenberg
This month the PNA Spotlight shines on Dr. Yuval Eisenberg. Dr. Eisenberg graduated from Rush Medical College at Rush University Medical Center in 2009. He works in Chicago, IL and two other locations and specializes in internal medicine as well as endocrinology, diabetes & metabolism. Dr. Eisenberg is also affiliated with the University of Illinois Hospital Health & Science Center. He was kind enough to answer some of our questions:
What inspired you to choose your career path?
My career path was guided by my interaction with patients and my mentors. The highlight of my medical school training was helping to diagnose a young man suffering from multiple endocrine neoplasia type 1 (MEN1), a rare genetic disorder causing multiple tumors, including a pituitary adenoma. Listening to his concerns and thinking outside the box, I helped provide him with the correct diagnosis and treatment plan – and started my journey into endocrinology. I have been fortunate to work with excellent clinician-educators in my career. Learning about and observing the care of patients with endocrine-related problems was fascinating and rewarding. The farther I got in my training, the more I realized that endocrinology was my passion and that patients with pituitary disorders would be my sub-focus. Patients with pituitary disease are a unique population who are in need of education, support and reassurance at diagnosis – and they often require long-term follow-up. This allows for time to develop a bond of trust; an aspect of medical practice I thoroughly enjoy.
Safeguarding the nose during pituitary tumor surgery
Pituitary tumors are typically removed through the nose during endoscopic transnasal transsphenoidal surgery. Although minimally invasive, that approach requires expertise to minimize surgical trauma to the nose. Fortunately, surgeons are using new techniques that help safeguard the nose and maximize patients’ quality of life after surgery.
“The tendency now is to be less invasive in the approach through the nose,” explains Dr. Carlos D. Pinheiro Neto, a Mayo Clinic ENT/head and neck surgeon. “A very aggressive approach can cause chronic nasal crusting and infections, scabbing, decreased sense of smell and taste, and changes in the nose’s appearance.”
In endoscopic transnasal transsphenoidal surgery, a small surgical camera and surgical instruments are placed through the nostrils to access the tumor through the sinuses. Mayo Clinic was among the first institutions to extensively research the approach. As initially developed, the procedure involved extensive nasal resection.
“The idea was to create a maximum opening of the sinuses to allow neurosurgeons to reach and remove the tumor from the skull base,” Dr. Pinheiro Neto says. “The nasal physiology and sinus symptoms after the surgery were not a priority — the nose was just a corridor to the tumor.”
Now, Dr. Pinheiro Neto is pioneering surgical techniques that minimize resection of the nasal and sinus structures. One involves leaving intact the middle turbinate, which plays important roles in nasal airflow, warming and filtering air to the lungs, and smelling. Another is using a nasal-floor graft to provide a seal between the nose and brain after tumor removal. The standard procedure when cerebrospinal fluid leaks during surgery involves a nasal septal flap created from the septum — the tissue that separates the nostrils’ two airways.
“Nasal graft is much better for patients. It avoids the exposure of the nasal septum cartilage, so there is less crusting and faster healing,” Dr. Pinheiro-Neto says. “Nasal septal flaps can also cause a structural collapse in the nasal bridge and increase the risk of septal perforations. Since changing our paradigm from nasal septal flap for pituitary surgery, our leak rate is 0.1%.”
The new techniques are based on research conducted in Mayo Clinic’s anatomy laboratory. Those lessons are translated to the operating room, where ENT/head and neck surgeons routinely work alongside neurosurgeons to remove pituitary tumors.
“That research has allowed us to achieve the same level of tumor resection and treatment outcomes, but with fewer complications,” Dr. Pinheiro-Nato says. “With time and experience, we have realized it’s possible to preserve most of the nose and still get good space in the back of the sinus for tumor removal.
“This is about improving patients’ quality of life,” Dr. Pinheiro-Neto says. “They can have a nasal procedure but after a few weeks of healing, the nose and nasal physiology, and the sinuses, are as good as ever before.”
Stanford Hosts Pituitary Patient Education Day
Stanford University invites the public to their free pituitary patient education day, to be held both in-person and via zoom on Saturday November 9th, 2024. The event will run from 8am-5pm and will take place in the Assembly Hall at Stanford Hospital.
The course co-directors include neurosurgeon Juan C. Fernandez-Miranda, MD (a longtime member of the PNA), and endocrinologist Julia Chang, MD. Topics to be discussed include the function of the pituitary gland, endonasal endoscopic surgery, cavernous sinus surgery, radiotherapy, Cushing’s, acromegaly, prolactinoma and more.
Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support
Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.
Sign up to get dedicated support:
Patients: Sign up for support | Recorlev® (levoketoconazole)
HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)
Have more questions? Call for more support at 1-844-444-RCLV (7258)
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.
News Articles October 2024
New acromegaly drug on the horizon
A new drug for treatment and long-term maintenance therapy for acromegaly is now on the horizon. Crinetics Pharmaceuticals recently submitted its first new drug application (NDA) to the U.S. Food and Drug Administration for paltusotine, which is a once-daily oral selectively-targeted somatostatin receptor type 2 nonpeptide agonist.
Crinetics says researchers used data from from 18 clinical trials in the application, including two Phase 3 trials that evaluated paltusotine for acromegaly in medically untreated and treated patients. Patients tolerated the treatment well, the medication achieved biochemical control by maintaining IGF-1 levels and improved patients’ symptoms compared to placebo. The company says it expects to hear back from the FDA by December.
Paltusotine, is the first drug of its type to complete Phase 3 clinical development for acromegaly and is now in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Read the company’s press release here.
Can machine learning to predict hormone deficiency after pituitary surgery?
A study featured on Nature.com used machine learning algorithms to predict whether patients would develop arginine vasopressin deficiency after transsphenoidal surgery to remove a pituitary adenoma. Read more here: https://www.nature.com/articles/s41598-024-72486-w
Pituitary apoplexy strikes groom on wedding day
An article in People.com tells the story of a groom in England who had to leave his wedding reception early due to a severe headache – one that turned out to be a hemorrhaging pituitary tumor. Read more here: https://people.com/groom-migraine-wedding-day-tumor-popped-8718083
Researchers try to make synthetic oxytocin for pain relief
An article in the Focus.news looks at efforts to replicate the hormone oxytocin in the lab – in an effort to develop a painkiller that would be safer than opioids. Read more here: https://www.thefocus.news/lifestyle/scientists-are-hoping-to-replicate-the-cuddle-hormone-for-healthy-long-term-pain-relief/
PNA Spotlight: Dr. Leena Shahla
This month the PNA Spotlight focuses on endocrinologist Dr. Leena Shahla, director of the Duke Pituitary Center, part of Duke Health in Durham, North Carolina. The program is listed by the PNA as a center of pituitary excellence. Dr. Shahla graduated medical school at Al-Baath University (in Homs, Syria), did her residency in internal medicine at St. Joseph’s at New York Medical College, and completed a fellowship in endocrinology at the University of Massachusetts Medical School. Her pituitary focus has grown significantly over the years. She initiated the pituitary tumor board at the University of Florida, Jacksonville, and later built the pituitary clinic at the University of Arizona, Phoenix. She arrived at Duke this past July. Dr. Shahla was kind enough to answer a few questions from the PNA. Below is the conversation.
Please tell us about your work at Duke.
At Duke, I am the neuroendocrinologist and medical director of Duke Pituitary Center. Our multidisciplinary team includes specialists in neurosurgery, neuro-ophthalmology, ENTs, neuro-oncology, and neuro-radiology. We run a multi-disciplinary clinic. When patients visit for evaluation, they often start with visual field testing, followed by appointments with me and one of the neurosurgeons, all in one place. We all collaborate closely behind the scenes to make the best plan for each patient.
What inspired you to choose this career path?
My interest in hormones and their role in regulating various physiological systems led me to specialize in endocrinology. And then, as I realized the significant impact of the pituitary on the endocrine system, I found the challenge of diagnosing and treating pituitary conditions fascinating, much like solving a complex puzzle. So ultimately, that inspired me to specialize in pituitary disorders.
What is the primary focus of your work or research?
We’re working on a study on the link between hypogonadism and prolactinoma. We are also going to be looking into early diagnosis of Cushing’s and acromegaly.
How has endocrinology evolved since you got into it, and where do you think it’s going?
Medicine today is more advanced than ever. Especially in my specialty, there have been advancements in pituitary-focused diagnostic tests and new treatments continue to emerge. This progress is especially beneficial for complex cases that previously had limited treatment options. The field is moving forward with studies and clinical trials underway. Cushing’s and acromegaly are rare diseases and often leave patients suffering for years before diagnosis. However, with greater public awareness and improved testing, patients are being diagnosed earlier.
What should patients know about endocrinology? What needs more awareness?
Cushing’s Syndrome and acromegaly deserve more awareness, as many patients go undiagnosed for long periods. Not all cases present with obvious symptoms making it crucial for primary care physicians and other providers to recognize early signs. When patients are diagnosed in advanced stages, treatment becomes more challenging. Raising awareness can guide physicians to screen for Cushing’s syndrome and acromegaly or refer patients to endocrinology. This proactive approach can help us identify, diagnose, and treat patients sooner.
What are some of the signs that doctors and patients should be looking for, for acromegaly and Cushing’s?
Both patients and providers should be aware of certain signs and symptoms, although they can be subtle or develop gradually.
For Cushing’s, signs could be unexplained weight gain, easy bruising, muscle weakness, mood changes (anxiety, depression, irritability), uncontrolled diabetes, or hypertension.
For acromegaly, some of signs are facial changes, hand and feet growth (increased ring or shoe size), joint pain and swelling, tingling in hands, jaw changes or pain, and widening of spaces between the teeth.
Early detection of these signs combined with diagnostic tests can help lead to timely intervention and management
What would you like to convey about yourself to your patients?
I believe that the doctor-patient relationship is built on communication, empathy, and trust. I am thorough in my approach, and when I meet patients, especially for the first time, I prioritize listening to their concerns, making sure I answer their questions and explain their conditions clearly so they understand. And I involve them actively in the decision-making process.
Empathy is essential, especially during the diagnosis and early stages of treatment before patients start feeling better. They need support, hand-holding, and understanding because they are often struggling physically, mentally, and emotionally. It is important to listen to their concerns patiently and guide them without getting frustrated. While we may not be able to cure everything, we can keep the disease very well-controlled, allowing them to feel better and supported.
What made you want to get involved with the PNA?
I always wanted to be involved with the PNA because pituitary disorders are not that common, and this group provides invaluable support to patients. My goal is to contribute as much as possible to help patients and community providers recognize the disease early. Patients must be referred to centers with the right resources for diagnosis and treatment. At the end of the day, we all care deeply about our patients’ well-being.
PNA Highlights October 2024
“Your body holds deep wisdom. Trust in it. Learn from it. Nourish it. Watch your life transform and be healthy.”
– Bella Bleue
PNA Spotlight: Dr. Yuval Eisenberg
This month the PNA Spotlight shines on Dr. Yuval Eisenberg. Dr. Eisenberg graduated from Rush Medical College at Rush University Medical Center in 2009. He works in Chicago, IL and two other locations and specializes in internal medicine as well as endocrinology, diabetes & metabolism. Dr. Eisenberg is also affiliated with the University of Illinois Hospital Health & Science Center. He was kind enough to answer some of our questions:
What inspired you to choose your career path?
My career path was guided by my interaction with patients and my mentors. The highlight of my medical school training was helping to diagnose a young man suffering from multiple endocrine neoplasia type 1 (MEN1), a rare genetic disorder causing multiple tumors, including a pituitary adenoma. Listening to his concerns and thinking outside the box, I helped provide him with the correct diagnosis and treatment plan – and started my journey into endocrinology. I have been fortunate to work with excellent clinician-educators in my career. Learning about and observing the care of patients with endocrine-related problems was fascinating and rewarding. The farther I got in my training, the more I realized that endocrinology was my passion and that patients with pituitary disorders would be my sub-focus. Patients with pituitary disease are a unique population who are in need of education, support and reassurance at diagnosis – and they often require long-term follow-up. This allows for time to develop a bond of trust; an aspect of medical practice I thoroughly enjoy.
Safeguarding the nose during pituitary tumor surgery
Pituitary tumors are typically removed through the nose during endoscopic transnasal transsphenoidal surgery. Although minimally invasive, that approach requires expertise to minimize surgical trauma to the nose. Fortunately, surgeons are using new techniques that help safeguard the nose and maximize patients’ quality of life after surgery.
“The tendency now is to be less invasive in the approach through the nose,” explains Dr. Carlos D. Pinheiro Neto, a Mayo Clinic ENT/head and neck surgeon. “A very aggressive approach can cause chronic nasal crusting and infections, scabbing, decreased sense of smell and taste, and changes in the nose’s appearance.”
In endoscopic transnasal transsphenoidal surgery, a small surgical camera and surgical instruments are placed through the nostrils to access the tumor through the sinuses. Mayo Clinic was among the first institutions to extensively research the approach. As initially developed, the procedure involved extensive nasal resection.
“The idea was to create a maximum opening of the sinuses to allow neurosurgeons to reach and remove the tumor from the skull base,” Dr. Pinheiro Neto says. “The nasal physiology and sinus symptoms after the surgery were not a priority — the nose was just a corridor to the tumor.”
Now, Dr. Pinheiro Neto is pioneering surgical techniques that minimize resection of the nasal and sinus structures. One involves leaving intact the middle turbinate, which plays important roles in nasal airflow, warming and filtering air to the lungs, and smelling. Another is using a nasal-floor graft to provide a seal between the nose and brain after tumor removal. The standard procedure when cerebrospinal fluid leaks during surgery involves a nasal septal flap created from the septum — the tissue that separates the nostrils’ two airways.
“Nasal graft is much better for patients. It avoids the exposure of the nasal septum cartilage, so there is less crusting and faster healing,” Dr. Pinheiro-Neto says. “Nasal septal flaps can also cause a structural collapse in the nasal bridge and increase the risk of septal perforations. Since changing our paradigm from nasal septal flap for pituitary surgery, our leak rate is 0.1%.”
The new techniques are based on research conducted in Mayo Clinic’s anatomy laboratory. Those lessons are translated to the operating room, where ENT/head and neck surgeons routinely work alongside neurosurgeons to remove pituitary tumors.
“That research has allowed us to achieve the same level of tumor resection and treatment outcomes, but with fewer complications,” Dr. Pinheiro-Nato says. “With time and experience, we have realized it’s possible to preserve most of the nose and still get good space in the back of the sinus for tumor removal.
“This is about improving patients’ quality of life,” Dr. Pinheiro-Neto says. “They can have a nasal procedure but after a few weeks of healing, the nose and nasal physiology, and the sinuses, are as good as ever before.”
Stanford Hosts Pituitary Patient Education Day
Stanford University invites the public to their free pituitary patient education day, to be held both in-person and via zoom on Saturday November 9th, 2024. The event will run from 8am-5pm and will take place in the Assembly Hall at Stanford Hospital.
The course co-directors include neurosurgeon Juan C. Fernandez-Miranda, MD (a longtime member of the PNA), and endocrinologist Julia Chang, MD. Topics to be discussed include the function of the pituitary gland, endonasal endoscopic surgery, cavernous sinus surgery, radiotherapy, Cushing’s, acromegaly, prolactinoma and more.
Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support
Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.
Sign up to get dedicated support:
Patients: Sign up for support | Recorlev® (levoketoconazole)
HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)
Have more questions? Call for more support at 1-844-444-RCLV (7258)
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.
October 2024 Research Articles
Pituitary Tumors
Duru M, Demir AN, Oz A, Kargin OA, Altunc AT, Demirel O, Arslan S, Kizilkilic O, Poyraz BC, Kadioglu P.J Endocrinol Invest. 2024 Oct 3. doi: 10.1007/s40618-024-02442-y. Online ahead of print.
Xu L, Lei Z, Wang Q, Jiang Q, Xing B, Li X, Guo X, Wang Z, Li S, Huang Y, Lei T.Antioxid Redox Signal. 2024 Oct 3. doi: 10.1089/ars.2024.0611. Online ahead of print.
Beyond Epistaxis: A Rare Case of Ectopic Sinonasal Adamantinomatous Craniopharyngioma.
Selva Kumaran K, Shamsudin NS, Dalip Singh HS, Devesahayam PR.Cureus. 2024 Sep 1;16(9):e68357. doi: 10.7759/cureus.68357. eCollection 2024 Sep.
Posterior pituitary tumors and other rare entities involving the pituitary gland.
Roncaroli F, Giannini C.Brain Pathol. 2024 Sep 30:e13307. doi: 10.1111/bpa.13307. Online ahead of print.PMID: 39350562 Review.
Pituitary Apoplexy in Pregnancy: Neonatal Implications.
Megan Y, Melissa S.Neoreviews. 2024 Oct 1;25(10):e660-e663. doi: 10.1542/neo.25-10-e660.
Zaher M, Kolmetzky DW, Al-Atrache Z, Vimawala S, Kolia NR, Godil SS.J Neurosurg Case Lessons. 2024 Sep 30;8(14):CASE24326. doi: 10.3171/CASE24326. Print 2024 Sep 30.
Zhang L, Yan S, Xie SK, Wei YT, Liu HP, Li Y, Wu HB, Wang HL, Xu PF.Endocr Connect. 2024 Sep 1:EC-24-0378. doi: 10.1530/EC-24-0378. Online ahead of print.
Acromegaly
Aliyeva T, Muniz J, Soares GM, Firdausa S, Mirza L.Pituitary. 2024 Oct 1. doi: 10.1007/s11102-024-01461-5. Online ahead of print.
Cushing’s
Braun LT, Vogel F, Nowak E, Rubinstein G, Zopp S, Ritzel K, Beuschlein F, Reincke M.Eur J Endocrinol. 2024 Oct 1:lvae127. doi: 10.1093/ejendo/lvae127. Online ahead of print.
Pituitary Surgery
De Nigris Vasconcellos F, Vilela MAD, Torrico FG, Scalise MA, Vargas VPS, Mendieta CD, Pichardo-Rojas P, Rosi MEA, Fleury LT, de Brito Rebelo ND, Benjamin C, Sheehan JP.Acta Neurochir (Wien). 2024 Oct 2;166(1):392. doi: 10.1007/s00701-024-06296-4.PMID: 39356336 Review.
Editor’s note: Dr. Sheehan is a member of the PNA.
Hormonal Health
Shimon I.Rev Endocr Metab Disord. 2024 Oct 2. doi: 10.1007/s11154-024-09902-z. Online ahead of print.PMID: 39356415 Review.
Saadeh NA, Obeidat M, Shboul M.Appl Clin Genet. 2024 Sep 26;17:143-149. doi: 10.2147/TACG.S466919. eCollection 2024.
PNA Spotlight: Dr. Yuval Eisenberg
This month the PNA Spotlight shines on Dr. Yuval Eisenberg. Dr. Eisenberg graduated from Rush Medical College at Rush University Medical Center in 2009. He works in Chicago, IL and two other locations and specializes in internal medicine as well as endocrinology, diabetes & metabolism. Dr. Eisenberg is also affiliated with the University of Illinois Hospital Health & Science Center. He was kind enough to answer some of our questions:
What inspired you to choose your career path?
My career path was guided by my interaction with patients and by my mentors. The highlight of my medical school training was helping to diagnose a young man suffering from multiple endocrine neoplasia type 1 (MEN1), a rare genetic disorder causing multiple tumors, including a pituitary adenoma. Listening to his concerns and thinking outside the box, I helped provide him with the correct diagnosis and treatment plan – and started my journey into endocrinology. I have been fortunate to work with excellent clinician-educators in my career. Learning about and observing the care of patients with endocrine-related problems was fascinating and rewarding. The farther I got in my training, the more I realized that endocrinology was my passion and that patients with pituitary disorders would be my sub-focus. Patients with pituitary disease are a unique population who are in need of education, support and reassurance at diagnosis – and they often require long-term follow-up. This allows for time to develop a bond of trust; an aspect of medical practice I thoroughly enjoy.
What is the primary focus of your work/research?
My main focus is my clinical endocrinology practice, and I see a variety of patients, but I have a specialized interest in patients with pituitary disorders. My research interest is in the hormone oxytocin and how it might affect patients with pituitary hormone deficiencies (hypopituitarism).
What do you consider to be the future of your field?
In my opinion, the future is in specialized and individualized expert care when providing for patients with pituitary disorders. Given the rarity of these diseases, patients are best served by providers with interest and experience. Also, the more we know about pituitary tumors and the genetics behind them, the better we will be able to predict patient outcomes and tailor our therapies.
What should patients know about your field/what deserves more recognition/awareness?
My feeling is that patients need to know that they can/should advocate to get the care they deserve from providers with interest and experience in caring for individuals with their condition. They should also utilize the excellent patient-centered resources (like the PNA) to help educate and direct their care.
What would you like to convey about yourself to your patients?
The best part of my job is helping patients (and their families) understand their condition, their prognosis and their options. It’s tremendously rewarding to help someone feel more comfortable with what is often a completely foreign, and sometimes scary sounding group of diseases. I strive to always spend the time and energy needed to make patients feel more at ease with and educated about their disease.
- Why did you get involved with the PNA and what is the extent of your involvement?
Early in my career, I became excited to become more involved. My mentor has also been involved in the PNA for many years and recommended I become involved, as he found it an excellent resource for patients and providers.
Available Now!

The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.
Xeris Pharmaceuticals is valued member of the PNA
Continuing Education Program
